1 / 8

Optimizing Hyperglycemia Management with SGLT2 Inhibitors: New Perspectives

Explore the latest ADA/EASD position statements on antihyperglycemic therapy in Type 2 Diabetes Mellitus. Discover the impact of SGLT2 inhibitors on weight reduction, glycemic control, cardiovascular endpoints, all-cause mortality, and heart failure hospitalizations. Evaluate adverse events associated with Dapagliflozin in randomized trials. Gain insights into improving diabetes management with these innovative therapies.

jonah-duke
Download Presentation

Optimizing Hyperglycemia Management with SGLT2 Inhibitors: New Perspectives

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ADA/EASD Position Statement: Approach to Hyperglycemia Management

  2. ADA/EASD Position Statement: Antihyperglycemic Therapy in T2DM

  3. SGLT2 Inhibitors: Weight Reduction in Randomized Trials as Add-On to Metformin

  4. SGLT2 Inhibitors: Glycemic Control Comparison as Add-On to Metformin

  5. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on Individual CV Endpoints

  6. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on All-Cause Mortality and HF Hospitalization

  7. AEs in Pooled, Placebo-Controlled Studies of Dapagliflozin

  8. Abbreviations

More Related